IP Library Granted Patent US 6,953,853
Granted Patent B2
US 6,953,853 · App. 10/467,832 · Granted Oct 11, 2005

Phthalazinone-piperidino-derivatives as PDE4 inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,953,853
App. No.
10/467,832
Granted
Oct 11, 2005
Kind
B2
Abstract

The compounds of a formula I, in which the given substituents have the meanings as given in the description, are novel effective PDE4 inhibitors

Claims (224)

1. A compound of formula I

in which

R1 and R2 are both hydrogen or together form an additional bond,

R3 represents a benzene derivative of formula (a) or (b)

 wherein

R4 is 1-4C-alkoxy or 1-4C-alkoxy which is completely or predominantly substituted by fluorine,

R5 is 1-8C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, or 1-4C-alkoxy which is completely or predominantly substituted by fluorine,

R6 is 1-4C-alkoxy, 3-5C-cycloalkoxy, 3-5C-cycloalkylmethoxy, or 1-4C-alkoxy which is completely or predominantly substituted by fluorine,

R7 is 1-4C-alkyl and

R8 is hydrogen or 1-4C-alkyl,

or wherein

R7 and R8 together, and with inclusion of the two carbon atoms, to which they are bonded, form a spiro-linked 5-, 6- or 7-membered hydrocarbon ring, optionally interrupted by an oxygen or sulphur atom,

R9 is —S(O) 2 —R10, —S(O) 2 —(CH 2 ) n —R11, —(CH 2 ) m —S(O) 2 —R12, —C(O)R13, —C(O)—(CH 2 ) n —R14, —(CH 2 ) m —C(O)—R15, Hetaryl, Aryl1 or Aryl2-1-4C-alkyl,

R10 is 1-4C-alkyl, 5-dimethylaminonaphthalin-1-yl, —N(R16)R17, phenyl or phenyl substituted by R18 and/or R19,

R11 is —N(R16)R17,

R12 is —N(R16)R17,

R13 is 1-4C-alkyl, hydroxycarbonyl-1-4C-alkyl, phenyl, pyridyl, 4-ethyl-piperazin-2,3-dion-1-yl or —N(R16)R17,

R14 is —N(R16)R17,

R15 is —N(R16)R17, phenyl or phenyl substituted by R18 and/or R19 and/or R20,

R16 and R17 are independent from each other and are hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkylmethyl, phenyl or phenyl substituted by R18 and/or R19 and/or R20, or R16 and R17 together and with inclusion of the nitrogen atom to which they are bonded, form a 4-morpholinyl-, 1-pyrrolidinyl-, 1-piperidinyl-, 1-hexahydroazepino- or a 1-piperazinyl-ring of formula (c)

 wherein

R21 is pyrid-4-yl, pyrid-4-ylmethyl, 1-4C-alkyl-dimethylamino, dimethylaminocarbonylmethyl, N-methyl-piperidin- 4-yl, 4-morpholino-ethyl or tetrahydrofuran-2-ylmethyl,

R18 is halogen, nitro, cyano, carboxyl, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyl, amino, mono- or di-1-4C-alkylamino, aminocarbonyl 1-4C-alkylcarbonylamino or mono- or di-1-4C-alkylaminocarbonyl,

R19 is halogen, amino, nitro, 1-4C-alkyl or 1-4C-alkoxy,

R20 is halogen,

Hetaryl is pyrimidin-2-yl, thieno-[2,3-d]pyrimidin-4-yl, 1-methyl-1H-pyrazolo-[3,4-d]pyrimidin-4-yl, thiazolyl, imidazolyl or furanyl,

Aryl1 is pyridyl, phenyl or phenyl substituted by R18 and/or R19,

Aryl2 is pyridyl, phenyl, phenyl substituted by R18 and/or R19, 2-oxo-2H-chromen-7-yl or 4-(1,2,3-thiadiazol-4-yl)phenyl,

n is an integer from 1 to 4,

m is an integer from 1 to 4,

or a hydrate, salt or hydrate of a salt thereof.

2. A compound of formula I according to claim 1 , in which

R1 and R2 are both hydrogen or together form an additional bond,

R3 represents a benzene derivative of formula (a) or (b)

 wherein

R4 is 1-4C-alkoxy or 1-4C-alkoxy which is completely or predominantly substituted by fluorine,

R5 is 1-8C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, or 1-4C-alkoxy which is completely or predominantly substituted by fluorine,

R6 is 1-4C-alkoxy, 3-5C-cycloalkoxy, 3-5C-cycloalkylmethoxy, or 1-4C-alkoxy which is completely or predominantly substituted by fluorine,

R7 is 1-4C-alkyl and

R8 is hydrogen or 1-4C-alkyl,

or wherein

R7 and R8 together and with inclusion of the two carbon atoms, to which they are bonded, form a spiro-linked 5-, 6- or 7-membered hydrocarbon ring, optionally interrupted by an oxygen or sulphur atom,

R9 is —S(O) 2 —R10, —S(O) 2 —(CH 2 ) n —R11, —(CH 2 ) m —S(O) 2 —R12, —C(O)R13, —C(O)—(CH 2 ) n —R14, —(CH 2 ) m —C(O)—R15, Hetaryl, Aryl1 or Aryl2-1-4C-alkyl,

R10 is 1-4C-alkyl, 5-dimethylaminonaphthalin-1-yl, —N(R16)R17, phenyl or phenyl substituted by R18 and/or R19,

R11 is —N(R16)R17,

R12 is —N(R16)R17,

R13 is 1-4C-alkyl, hydroxycarbonyl-1-4C-alkyl, phenyl, pyridyl, 4-ethyl-piperazin-2,3-dion-1-yl or —N(R16)R17,

R14 is —N(R16)R17,

R15 is —N(R16)R17, phenyl, phenyl substituted by R18 and/or R19 and/or R20,

R16 and R17 are independent from each other and are hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkylmethyl or phenyl, or R16 and R17 together, and with inclusion of the nitrogen atom to which they are bonded, form a 4-morpholinyl-, 1-pyrrolidinyl-, 1-piperidinyl-, 1-hexahydroazepino- or a 1-piperazinyl-ring of formula (c)

 wherein

R21 is pyrid-4-yl, pyrid-4-ylmethyl, 1-4C-alkyl-dimethylamino, dimethylaminocarbonylmethyl, N-methyl-piperidin-4-yl, 4-morpholino-ethyl or tetrahydrofuran-2-ylmethyl,

R18 is halogen, nitro, cyano, carboxyl, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyl, amino, mono- or di-1-4C-alkylamino, aminocarbonyl 1-4C-alkylcarbonylamino or mono- or di-1-4C-alkylaminocarbonyl,

R19 is halogen, amino, nitro, 1-4C-alkyl or 1-4C-alkoxy,

R20 is halogen,

Hetaryl is pyrimidin-2-yl, thieno-[2,3-d]pyrimidin-4-yl, 1-methyl-1H-pyrazolo-[3,4-d]pyrimidin-4-yl, thiazolyl, imidazolyl or furanyl,

Aryl1 is pyridyl, phenyl or phenyl substituted by R18 and/or R19,

Aryl2 is pyridyl, phenyl, phenyl substituted by R18 and/or R19, 2-oxo-2H-chromen-7-yl or 4-(1,2,3-thiadiazol-4-yl)phenyl,

n is an integer from 1 to 4,

m is an integer from 1 to 4,

or a hydrate, salt or hydrate of a salt thereof.

3. A compound of formula I according to claim 1 , in which

R1 and R2 are both hydrogen or together form an additional bond,

R3 represents a benzene derivative of formula (a) or (b)

 wherein

R4 is 1-4C-alkoxy or 1-2C-alkoxy which is completely or predominantly substituted by fluorine,

R5 is 1-4C-alkoxy,

R6 is 1-2C-alkoxy or 1-2C-alkoxy which is completely or predominantly substituted by fluorine,

R7 is methyl and

R8 is hydrogen,

or wherein

R7 and R8 together and with inclusion of the two carbon atoms, to which they are bonded, form a spiro-linked cyclopentane, cyclohexane, tetrahydrofurane or tetrahydropyran ring,

R9 is —S(O) 2 —R10, —S(O) 2 —(CH 2 ) n —R11, —C(O)R13, —C(O)—(CH 2 ) n —R14, —(CH 2 ) m —C(O)—R15, Hetaryl, Aryl1 or Aryl2-1-2C-alkyl,

R10 is 1-4C-alkyl, 5-dimethylaminonaphthalin-1-yl, —N(R16)R17, phenyl or phenyl substituted by R18,

R11 is —N(R16)R17,

R13 is 1-4C-alkyl, hydroxycarbonyl-1-4C-alkyl, phenyl, pyridyl, 4-ethyl-piperazin-2,3-dion-1-yl or —N(R16)R17,

R14 is —N(R16)R17,

R15 is —N(R16)R17, phenyl or phenyl substituted by R18 and/or R19 and/or R20,

R16 and R17 are independent from each other and are hydrogen, 1-4C-alkyl, phenyl or phenyl substituted by R18 and/or R19 and/or R20, or R16 and R17 together and with inclusion of the nitrogen atom to which they are bonded, form a 4-morpholinyl ring, a 1-piperidinyl ring or a 1-piperazinyl ring of formula (c)

 wherein

R21 is pyrid-4-yl, pyrid-4-ylmethyl, dimethylamino-1-4C-alkyl, dimethylaminocarbonylmethyl, N-methyl-piperidin-4-yl, 4-morpholino-ethyl or tetrahydrofuran-2-ylmethyl,

R18 is halogen, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxycarbonyl,

R19 is halogen, amino, nitro, 1-4C-alkyl or 1-4C-alkoxy,

R20 is halogen,

Hetaryl is pyrimidin-2-yl, thieno-[2,3-d]pyrimidin-4-yl or 1-methyl-1H-pyrazolo-[3,4-d]pyrimidin-4-yl,

Aryl1 is pyridyl, phenyl or phenyl substituted by R18,

Aryl2 is pyridyl, phenyl, phenyl substituted by R18, 2-oxo-2H-chromen-7-yl or 4-(1,2,3-thiadiazol-4-yl)phenyl,

n is 1 or 2,

m is 1 or 2,

or a hydrate, salt or hydrate of a salt thereof.

4. A compound of formula I according to claim 1 , in which

R1 and R2 are both hydrogen or together form an additional bond,

R3 represents a benzene derivative of formula (a) or (b)

 wherein

R4 is 1-2C-alkoxy or 1-2C-alkoxy which is completely or predominantly substituted by fluorine,

R5 is 1-4C-alkoxy,

R6 is 1-2C-alkoxy or 1-2C-alkoxy which is completely or predominantly substituted by fluorine,

R7 is methyl and

R8 is hydrogen,

or wherein

R7 and R8 together and with inclusion of the two carbon atoms, to which they are bonded, form a spiro-linked cyclopentane, cyclohexane, tetrahydrofurane or tetrahydropyran ring,

R9 is —S(O) 2 —10, —S(O) 2 —(CH 2 ) n —R11, —C(O)R13, —C(O)—(CH 2 ) n —R14, —(CH 2 ) m —C(O)—R15, Hetaryl, Aryl1 or Aryl2-1-2C-alkyl,

R10 is 1-4C-alkyl, 5-dimethylaminonaphthalin-1-yl, —N(R16)R17, phenyl or phenyl substituted by R18,

R11 is —N(R16)R17,

R13 is 14C-alkyl, hydroxycarbonyl-1-4C-alkyl, phenyl, pyridyl, 4-ethyl-piperazin-2,3-dion-1-yl or —N(R16)R17,

R14 is —N(R16)R17,

R15 is —N(R16)R17, phenyl or phenyl substituted by R18 and/or R19 and/or R20,

R16 and R17 are independent from each other and are hydrogen, 1-4C-alkyl or phenyl, or —R16 and R17 together and with inclusion of the nitrogen atom to which they are bonded, form a 4-morpholinyl-, a 1-piperidinyl or a 1-piperazinyl-ring of formula (c)

 wherein

R21 is pyrid-4-yl, pyrid-4-ylmethyl, 1-4C-alkyl-dimethylamino, dimethylaminocarbonylmethyl, N-methyl-piperidin-4-yl, 4-morpholino-ethyl or tetrahydrofuran-2-ylmethyl,

R18 is halogen, nitro, 1-4C-alkyl, trifluoromethyl or 1-4C-alkoxy,

R19 is halogen, amino, nitro, 1-4C-alkyl or 1-4C-alkoxy,

R20 is halogen,

Hetaryl is pyrimidin-2-yl, thieno-[2,3-d]pyrimidin-4-yl or 1-methyl-1H-pyrazolo-[3,4-d]pyrimidin-4-yl,

Aryl1 is pyridyl, phenyl or phenyl substituted by R18,

Aryl2 is pyridyl, phenyl, phenyl substituted by R18, 2-oxo-2H-chromen-7-yl or 4-(1,2,3-thiadiazol-4-yl)phenyl,

n is 1 or 2,

m is 1 or 2,

or a hydrate, salt or hydrate of a salt thereof.

5. A compound of formula I according to claim 1 , in which

R1 and R2 together form an additional bond,

R3 represents a benzene derivative of formula (a) or (b)

 wherein

R4 is 1-4C-alkoxy,

R5 is 1-4C-alkoxy,

R6 is 1-2C-alkoxy,

R7 is methyl and

R8 is hydrogen,

R9 is —S(O) 2 —R10, —C(O)R13, —C(O)—(CH 2 ) n —R14, —(CH 2 ) m —C(O)—R15, Hetaryl, Aryl1 or Aryl2-1-2C-alkyl,

R10 is 1-4C-alkyl, 5-dimethylaminonaphthalin-1-yl, phenyl or phenyl substituted by R18,

R13 is 1-4C-alkyl, hydroxycarbonyl-1-4C-alkyl, pyridyl, 4-ethyl-piperazin-2,3-dion-1-yl or —N(R16)R17,

R14 is —N(R16)R17,

R15 is —N(R16)R17, phenyl or phenyl substituted by R18 and/or R19 and/or R20,

R16 and R17 are independent from each other and are hydrogen, 1-4C-alkyl, phenyl or phenyl substituted by R18 and/or R19 and/or R20, or R16 and R17 together and with inclusion of the nitrogen atom to which they are bonded, form a 4-morpholinyl ring or a 1-piperazinyl ring of formula (c)

 wherein

R21 is dimethylamino-1-4C-alkyl,

R18 is halogen, nitro, 1-4C-alkyl or 1-4C-alkoxycarbonyl,

R19 is amino,

R20 is halogen,

Hetaryl is pyrimidin-2-yl, thieno-[2,3-d]pyrimidin-4-yl or 1-methyl-1H-pyrazolo-[3,4-d]pyrimidin-4-yl,

Aryl1 is phenyl or phenyl substituted by R18,

Aryl2 is pyridyl, phenyl, 2-oxo-2H-chromen-7-yl or 4-(1,2,3-thiadiazol-4-yl)phenyl,

n is 1 or 2,

m is 1 or 2,

or a hydrate, salt or hydrate of a salt thereof.

6. A compound of formula I

in which

R1 and R2 together form an additional bond,

R3 represents a benzene derivative of formula (a) or (b)

 wherein

R4 is methoxy or ethoxy,

R5 is methoxy or ethoxy,

R6 is methoxy or ethoxy,

R7 is methyl and

R8 is hydrogen,

R9 is toluene-4-sulfonyl, methanesulfonyl, acetyl, 5oxo-pentanoic acid, pyridin-4-yl-carbonyl, tert-butylaminocarbonyl, phenylaminocarbonyl, 5-dimethylamino-naphthalene-1-sulfonyl, 4-nitrophenyl, pyridin-4-ylmethyl, morpholine-4-carbonyl, 2-(4-amino-3,5-dichlorophenyl)-2-oxo-ethyl, 1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl, thieno[2,3-d]pyrimidin-4-yl, pyrimidin-2-yl, 2-oxo-2H-chromen-7-ylmethyl, isopropyl, morpholin-4-yl-2-oxo-ethyl, phenethyl, pyridin-3-ylmethyl, pyridin-2-ylmethyl, pyridin-4-ylmethyl, 2-morpholin-4-ylethanoyl, 2-[(4-(2-dimethylaminoethyl)-piperazin-1-yl]-ethanoyl, isopropylaminocarbonylmethyl, 4ethyl-piperazine-2,3-dione-1-carbonyl, 4-(1,2,3-thiadiazol-4-yl-)benzyl, 4-ethoxycarbonylphenylamino-2-oxo-ethyl or aminocarbonylmethyl,

or a hydrate, salt or hydrate of a salt thereof.

7. A compound of formula I

in which

R1 and R2 together form an additional bond,

R3 represents a benzene derivative of formula (a) or (b)

 wherein

R4 is methoxy or ethoxy,

R5 is methoxy or ethoxy,

R6 is methoxy or ethoxy,

R7 is methyl and

R8 is hydrogen,

or wherein

R7 and R8 together and with inclusion of the two carbon atoms, to which they are bonded, form a cyclopentane or cyclohexan ring,

R9 is toluene-4-sulfonyl, methanesulfonyl, acetyl, 5oxo-pentanoic acid, pyridin-4-yl-carbonyl, tert-butylaminocarbonyl, phenylaminocarbonyl, 5-dimethylamino-naphthalene-1-sulfonyl, 4-nitrophenyl, pyridin-4-ylmethyl, morpholine-4-carbonyl, 2-(4-amino-3,5-dichlorophenyl)-2-oxo-ethyl, 1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl, thieno[2,3-d]pyrimidin-4-yl, pyrimidin-2-yl, 2-oxo-2H-chromen-7-ylmethyl, isopropyl, morpholin-4-yl-2-oxo-ethyl, phenethyl, pyridin-3-ylmethyl, pyridin-2-ylmethyl, pyridin-4-ylmethyl, 2-morpholin-4-ylethanoyl, 2-[4-(2-dimethylaminoethyl)-piperazin-1-yl]-ethanoyl, isopropylaminocarbonylmethyl, 4-ethyl-piperazine-2,3-dione-1-carbonyl or 4-(1,2,3-thiadiazol-4-yl-)benzyl,

or a hydrate, salt or hydrate of a salt thereof.

8. A compound of formula I according to claim 1 or a hydrate, salt or hydrate of a salt thereof, in which the hydrogen atoms in the positions 4a and 8a are cis-configurated.

9. A compound of formula I according to claim 1 or a hydrate, salt or hydrate of a salt thereof, in which the absolute configuration is S in the position 4a and R in the position 8a.

10. A compound of formula I according to claim 1 or a hydrate, salt or hydrate of a salt thereof, in which R3 represents a benzene derivative of formula (a).

11. A compound of formula I according to claim 1 , selected from the group consisting of

(4aS,8aR)-4-(3,4-Diethoxyphenyl)2-[1-(toluene-4-sulfonyl)-piperidin-4-yl]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one,

(4aS,8aR)-4-(3,4-Diethoxyphenyl)-2-(1-methanesulfonyl-piperidin-4-yl)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one,

(4aS,8aR)-2-(1-Acetyl-piperidin-4-yl)-4-(3,4-diethoxyphenyl)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one,

5-(4-[(4aS,8aR)-4-(3,4-Diethoxy-phenyl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-piperidin-1-yl)-5-oxo-pentanoic acid,

(4aS,8aR)-4-(3,4-Diethoxyphenyl)-2-[1-(1-pyridin-4-yl-methanoyl)-piperidin-4-yl]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one,

4-[(4aS,8aR)-4-(3,4-Diethoxyphenyl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-piperidine-1-carboxylic acid tert-butylamide,

4-[(4aS,8aR)-4-(3,4-Diethoxyphenyl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-piperidine-1-carboxylic acid phenylamide,

4-[(4aS,8aR)-4-(3,4-Dimethoxyphenyl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-piperidine-1-carboxylic acid tert-butylamide,

(cis)-4-[4-(7-Methoxy-2,2-dimethyl-2,3-dihydro-benzofuran-4-yl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-piperidine-1-carboxylic acid tert-butylamide,

(4aS,8aR)-4-(3,4-Dimethoxyphenyl)-2-[1-(5-dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one,

(4aS,8aR)-4-(3,4-Dimethoxyphenyl)-2-[1-(4-nitro-phenyl)-piperidin-4-yl]4a,5,8,8a-tetrahydro-2H-phthalazin-1-one,

(4aS,8aR)-4-(3,4-Dimethoxyphenyl)-2-(1-pyridin-4-ylmethyl-piperidin-4-yl)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one,

(4aS,8aR)-4-(3,4-Dimethoxyphenyl)-2-[1-(morpholine-4-carbonyl)-piperidin-4-yl]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one,

(4aS,8aR)-2-{1-[2-(4-Amino-3,5dichloro-phenyl)-2-oxo-ethyl]-piperidin-4-yl}-4-(3,4-dimethoxy-phenyl)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one,

4-(3,4-Dimethoxyphenyl)-2-[1-(1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-piperidin-4-yl]-4a,5,8,8a-tetrahydro-2H-naphthalen-1-one,

(4aS,8aR)-4-(3,4-Dimethoxyphenyl)-2-(1-thieno[2,3-d]pyrimidin-4-yl-piperidin-4-yl)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one,

(4aS,8aR)-4-(3,4-Dimethoxyphenyl)-2-(1-pyrimidin-2-yl-piperidin-4-yl)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one,

(4aS,8aR)-4-(3,4-Dimethoxyphenyl)-2-[1-(2-oxo-2H-chromen-7-ylmethyl)-piperidin-4-yl]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one,

(4aS,8aR)-4-(3,4-Dimethoxyphenyl)-2-[1-(2-morpholin-4-yl-2-oxo-ethyl)-piperidin-4-yl]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one,

(4aS,8aR)-4-(3,4-Dimethoxyphenyl)-2-(1-phenethyl-piperidin-4-yl)-4a,5,8,8tetrahydro-2H-phthalazin-1-one,

(4aS,8aR)4-(3,4-Diethoxyphenyl)-2-[1-(morpholine-4-carbonyl)-piperidin-4-yl]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one,

(4aS,8aR)-4-(3,4-Dimethoxyphenyl)-2-(1-pyridin-3-ylmethyl-piperidin-4-yl)-4a,5,8,8a-tetrahydro-2H-phthalazin-1 one,

(4aS,8aR)-4-(3,4-Dimethoxy-phenyl)-2-(1-pyridin-2-ylmethyl-piperidin-4-yl)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one,

(4aS,8aR)-4-(3,4-Diethoxyphenyl)-2-[1-(2-morpholin-4-yl-ethanoyl)-piperidin-4-yl]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one,

(4aS,8aR)-4-(3,4-Diethoxyphenyl)-2-(1-{2-[4-(2-dimethylamino-ethyl-piperazin-1-yl]-ethanoyl}-piperidin-4-yl)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one,

2-{4-[(4aS,8aR)-4-(3,4-Dimethoxyphenyl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-piperidin-1-yl}-2H-isopropyl-acetamide,

(4aS,8aR)-4-(3,4-Dimethoxyphenyl)-2-[1-(4-1,2,3-thiadiazol-4-yl-benzyl)-piperidin-4-yl]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one,

1-(1 {4-[(4aS,8aR)-4-(3,4-Dimethoxyphenyl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-piperidin-1-yl}-methanoyl)-4-ethyl-piperazine-2,3-dione,

4-(2{4-[(4aS,8aR)-4-(3,4-Dimethoxy-phenyl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-piperidin-1-yl}-ethanoylamino)-benzoic acid ethyl ester,

2-{4-[(4aS,8aR)-4-(3,4-Dimethoxyphenyl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-piperidin-1-yl}-acetamide,

and the hydrates, salts and hydrates of the salts thereof.

12. A compound of formula I according to claim 2 or a hydrate, salter hydrate of a salt thereof, in which the hydrogen atoms in the positions 4a and 8a are cis-configurated.

13. A compound of formula I according to claim 2 or a hydrate, salt or hydrate of a salt thereof, in which the absolute configuration is S in the position 4a and R in the position 8a.

14. A compound of formula I according to claim 2 or a hydrate, salt or hydrate of a salt thereof, in which R3 represents a benzene derivative of formula (a).

15. A compound of formula I according to claim 3 or a hydrate, salt or hydrate of a salt thereof, in which the hydrogen atoms in the positions 4a and 8a are cis-configurated.

16. A compound of formula I according to claim 3 or a hydrate, salt or hydrate of a salt thereof, In which the absolute configuration is S in the position 4a and P in the position 8a.

17. A compound of formula I according to claim 3 or a hydrate, salt or hydrate of a salt thereof, in which R3 represents a benzene derivative of formula (a).

18. A compound of formula I according to claim 4 or a hydrate, salt or hydrate of a salt thereof, in which the hydrogen atoms in the positions 4a and 8a are cis-configurated.

19. A compound of formula I according to claim 4 or a hydrate, salt or hydrate of a salt thereof, in which the absolute configuration is S in the position 4a and R in the position 8a.

20. A compound of formula I according to claim 4 or a hydrate, salt or hydrate of a salt thereof, in which R3 represents a benzene derivative of formula (a).

21. A compound of formula I according to claim 5 or a hydrate, salt or hydrate of a salt thereof, in which the hydrogen atoms in the positions 4a and 8a are cis-configurated.

22. A compound of formula I according to claim 5 or a hydrate, salt or hydrate of a salt thereof, in which the absolute configuration is S in the position 4a and R in the position 8a.

23. A compound of formula I according to claim 5 or a hydrate, salt or hydrate of a salt thereof, in which R3 represents a benzene derivative of formula (a).

24. A compound of formula I according to claim 6 or a hydrate, salt or hydrate of a salt thereof, in which the hydrogen atoms in the positions 4a and 8a are cis-configurated.

25. A compound of formula I according to claim 6 or a hydrate, salt or hydrate of a salt thereof, in which the absolute configuration is S in the position 4a and R in the position 8a.

26. A compound of formula I according to claim 6 or a hydrate, salt or hydrate of a salt thereof, in which R3 represents a benzene derivative of formula (a).

27. A compound of formula I according to claim 7 or a hydrate, salt or hydrate of a salt thereof, in which the hydrogen atoms in the positions 4a and 8a are cis-configurated.

28. A compound of formula I according to claim 7 or a hydrate, salt or hydrate of a salt thereof, in which the absolute configuration is S in the position 4a and R in the position 8a.

29. A compound of formula I according to claim 7 or a hydrate, salt or hydrate or a salt thereof, in which R3 represents a benzene derivative of formula (a).

Assignments (3)
CHANGE OF NAME Recorded Mar 26, 2013
From: NYCOMED GMBH
To: TAKEDA GMBH
Reel/Frame 030091/0737 →
CHANGE OF NAME Recorded Oct 10, 2008
From: ALTANA PHARMA AG
To: NYCOMED GMBH
Reel/Frame 021669/0109 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2003
From: GRUNDLER, GERHARD; SCHMIDT, BEATE; STERK, GEERT JAN
To: ALTANA PHARMA AG
Reel/Frame 014882/0482 →